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Abstract
Background: As more inhaled corticosteroid (ICS) devices become available, there may be
pressure for health-care providers to switch patients with asthma to cheaper inhaler devices. Our
objective was to evaluate impact on asthma control of inhaler device switching without an
accompanying consultation in general practice.
Methods:  This 2-year retrospective matched cohort study used the UK General Practice
Research Database to identify practices where ICS devices were changed without a consultation
for ≥5 patients within 3 months. Patients 6–65 years of age from these practices whose ICS device
was switched were individually matched with patients using the same ICS device who were not
switched. Asthma control over 12 months after the switch was assessed using a composite measure
including short-acting β-agonist and oral corticosteroid use, hospitalizations, and subsequent
changes to therapy.
Results: A total of 824 patients from 55 practices had a device switch and could be matched. Over
half (53%) of device switches were from dry powder to metered-dose inhalers. Fewer patients in
switched than matched cohort experienced successful treatment based on the composite measure
(20% vs. 34%) and more experienced unsuccessful treatment (51% vs. 38%). After adjusting for
possible baseline confounding factors, the odds ratio for treatment success in the switched cohort
compared with controls was 0.29 (95% confidence interval [CI], 0.19 to 0.44; p < 0.001) and for
unsuccessful treatment was 1.92 (95% CI, 1.47 to 2.56; p < 0.001).
Conclusion: Switching ICS devices without a consultation was associated with worsened asthma
control and is therefore inadvisable.
Background
Much of the costs of asthma are associated with subopti-
mally controlled disease [1-6]. By one estimate, based on
an analysis of several studies, one third of the direct med-
ical costs and three quarters of the total costs of asthma
can be attributed to uncontrolled disease [2]. For patients
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with persistent asthma, inhaled corticosteroids (ICS) are
considered to be the most effective controller medications
currently available [7]. A range of different molecules and
inhaler devices are marketed, and more are regularly being
developed, often resulting in several options for ICS deliv-
ery.
Each type of inhaler device has its advantages and disad-
vantages together with cost [8], and each requires a differ-
ent inhalation technique. In a recent review of inhaler
devices by Virchow et al (2008), device characteristics
were compared. Virchow et al suggested that the choice of
inhaler may be one reason why asthma remains poorly
controlled [9]. Patient training for each device and regular
checking of inhalation technique are, therefore, consid-
ered to be essential for optimal treatment delivery [8,10-
12]. In fact, many believe, and asthma management
guidelines reinforce, that an inhaler should not be pre-
scribed without confirming that the patient knows how to
use the device [11,13].
Prescription cost-containment measures are increasing in
many countries and, as more devices become available,
there may be pressure to switch patients to a cheaper
inhaler device [14]. Indeed, in some countries, such a sub-
stitution is mandated by current regulations, and patients
who do not accept the substitution have to pay the differ-
ence in cost. However, acquisition cost savings from a
substitution could be offset by costs related to deteriora-
tion in asthma control if the patient is unable or unwilling
to use the inhaler device properly.
The purpose of this retrospective database analysis was to
evaluate the impact on asthma control of inhaler device
switching without an accompanying consultation in gen-
eral practice in the United Kingdom (UK). Our hypothesis
was that, for patients with asthma, switching inhaler
device without a consultation is associated with worsened
clinical outcomes.
Methods
Study design
This 2-year retrospective matched cohort study included a
baseline period of 1 year before the date of ICS device
switch (index date) and an outcome period of 1 year after
the index date. Patient data were drawn from 1990–2004
records in the General Practice Research Database
(GPRD), a large computerized database of anonymized
longitudinal medical records from primary care in the Uk
[15]. The years of the switch and matched cohort analyzed
in this study are 1992 to 2003. This database includes
information for over 13 million patients, including 3.4
million active patients for whom data are currently being
gathered. Reports for each patient include demographic
data and event history, including date and type of event
with a description of the event and the corresponding
code. Information about the reason for a switch in device
is not recorded. Ethical approval was received from the
GPRD Scientific and Ethical Advisory Committee (Proto-
col 706R, 26.4.05).
Patients
Patients eligible for inclusion in this analysis were receiv-
ing ICS, were 6–65 years of age on the index date, and had
a recorded diagnosis of asthma and no record of chronic
obstructive pulmonary disease (COPD). We used the
GPRD to identify primary care practices where ICS inhaler
devices were switched without an accompanying consul-
tation on the same day for five or more patients within a
3-month period. Patients had to be registered at the prac-
tice for at least 1 year before and 1 year after the index
date. We included switches to inhaler devices that require
training to use, namely, from a dry powder inhaler to a
metered-dose inhaler, another brand of dry powder
inhaler, or a breath-actuated inhaler or from a breath-
actuated to a metered-dose inhaler or another brand of
breath-actuated inhaler. Patients changed to a device
recorded as 'generic' were excluded.
Each patient included in the analysis was individually
matched to another patient (from any practice) who was
receiving the same ICS device on the index date and met
the following six criteria: same sex, age within 5 years,
same smoking status, match on presence or absence of
rhinitis history, and, during the prior year, same number
of oral corticosteroid prescriptions and hospitalizations
for asthma.
Outcome measures
Outcome measures were analyzed for the year before
(baseline period or year 1) and the year after the index
date (outcome period or year 2). The primary outcome
measure was a composite measure of asthma control, as
defined in Table 1. Secondary outcome measures included
several individual elements of asthma-related health
resource utilization. The number of prescriptions/patient
per year was analyzed for inhaled short-acting β-agonist
and oral corticosteroids; in addition, the number of
doses/day of short-acting β-agonist was determined for
each patient based on the number of inhalers prescribed/
year and an assumed standard dose of salbutamol 200 μg
and terbutaline 500 μg. We also analyzed the number of
general practice consultations (physician and practice
nurse) for asthma, the number of hospital admissions for
asthma, and the number of hospital admissions for possi-
ble asthma, which were defined as nonspecific hospitali-
zation code and asthma-related code within a 1-week
window.
Other data recorded for each patient included assigned
socioeconomic status of the primary care practice and
other respiratory or confounding diagnoses. The dailyBMC Pulmonary Medicine 2009, 9:1 http://www.biomedcentral.com/1471-2466/9/1
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dose of ICS was calculated from the prescribing instruc-
tions on the first available prescription after the index
date.
Statistical analyses
Baseline characteristics of switched and matched control
patients were compared using t and χ2 tests as appropriate.
Median intended ICS dose, daily short-acting β-agonist
dose, and asthma consultation pattern during the baseline
year were compared for the two cohorts using the Mann-
Whitney U test. For comparison of change between year 1
and year 2, the paired t test (mean changes in short-acting
β-agonist use and asthma consultations) and χ2  test
(change or not in ICS dose or device from year 1 to year 2)
were used.
For comparisons of the primary outcome measure, in
addition to the unadjusted analyses, we used logistic
regression to correct for potential baseline confounders.
Binary regression models were constructed using as the
three outcome variables 1) successful vs. partially success-
ful/unsuccessful treatment, 2) unsuccessful treatment vs.
successful/partially successful treatment, and 3) subse-
quent change in ICS device or dose and, as explanatory
variables, cohort membership plus possible confounding
factors. Possible baseline confounders entered into the
model included 1) short-acting β-agonist use (average
daily use categorized as none, ≤0.5 doses/day, >0.5–2
doses/day, >2 doses/day); 2) asthma consultation rate
(categorized as: none, 1, 2, ≥3); 3) socioeconomic status
(in quintiles); and 4) prescribed ICS dose at switch (in
sensitivity analysis as incomplete data due to some
patients receiving vague prescribing instructions, catego-
rized as ≤400 μg/day, 401–800 μg/day, 801–2000 μg/day,
>2000 μg/day).
Results
Patients
We identified 112,090 patients with asthma in the GPRD
database who had a switch of ICS device (Figure 1). There
were 55 primary care practices in the database where a
switch in device without an accompanying consultation
occurred on five or more occasions over 3 months. Over-
all, at these 55 practices, 835 patients had a device switch,
and 824 could be matched according to our criteria. The
number of switches ranged from 5 to 127 per practice; ≥10
patients were switched at 24 practices, and ≥30 patients
were switched at 7 practices. Over half (53%) of the device
switches were from a dry powder to a metered-dose
inhaler (Table 2).
The switched and control cohorts were identical or com-
parable, as per the study protocol, with regard to the crite-
ria used for matching (Table 3). The rate of admissions
associated with a respiratory consultation was also similar
at baseline in the switched and control cohorts (5 vs. 9
patients with 6 vs. 10 admissions, respectively), as was the
presence of recorded gastroesophageal reflux or cardiovas-
cular disease (see Table 3).
The median intended dose of ICS at the index date was
similar for the two cohorts (see Table 3). Data for 601 of
824 patients (73%) in each cohort were used for these cal-
culations; it was not possible to quantify the daily dose for
the other 223 patients (27%) in each cohort because the
instruction 'as directed' was recorded for their ICS pre-
scriptions. Table 3 highlights that there were some differ-
ences (p < 0.05) between cohorts at baseline.
Outcomes
Fewer patients experienced successful treatment and more
patients experienced unsuccessful treatment in the
switched cohort than in the control cohort (Figure 2). The
likelihood of successful treatment for the switched group
was half that for the control group and fell to less than one
third that for the control group after adjusting for con-
founding factors (Table 4). No other variables were pre-
dictive of success. Including the ICS dose in the model
made no substantial difference: cohort membership
remained the only predictor of success, with switched hav-
Table 1: Definition of asthma control – a composite measure – over 12 months
Assessment of Asthma Control*
Criterion for the Composite Measure Successful Treatment
(All Criteria)
Partially Successful Treatment
(All Criteria)
Unsuccessful Treatment
(≥ 1 Criterion)
Mean SABA dose ≤0.5 dose/day 0.5 to ≤2 doses/day >2 doses/day
Oral corticosteroid use/yr None ≤2 courses ≥3 courses
Controller therapy Not changed Not changed Changed
Hospitalization† None None ≥1
SABA = short-acting β-agonist; 1 daily dose = salbutamol 200 μg or terbutaline 500 μg.
*Successful and partially successful treatment had to meet each criterion, while unsuccessful treatment could be defined by any one or more of the 
criteria.
†This includes any hospital attendance for asthma, including admission, emergency department, or outpatient department (hospital clinic) 
attendance.BMC Pulmonary Medicine 2009, 9:1 http://www.biomedcentral.com/1471-2466/9/1
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Study flow diagram showing patient selection for the switched cohort Figure 1
Study flow diagram showing patient selection for the switched cohort.BMC Pulmonary Medicine 2009, 9:1 http://www.biomedcentral.com/1471-2466/9/1
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ing significantly lower odds of success than control
patients (OR, 0.30; 95% CI, 0.20 to 0.45; p < 0.001).
The likelihood of unsuccessful treatment among switched
patients was almost double that for control patients (see
Table 4). Other variables predictive of unsuccessful treat-
ment were a greater use of short-acting β-agonist and
more asthma consultations at baseline. Including the ICS
dose in the model made no substantial difference (OR,
1.93; 95% CI, 1.46 to 2.55; p < 0.001).
Patients in the switched cohort were also more likely than
those in the control cohort to experience a subsequent
change in ICS device or dose in year 2 (see Table 4). Other
variables predictive of ICS change were short-acting β-ago-
nist use, socioeconomic status, and rate of asthma consul-
Table 2: Types of inhaled corticosteroid (ICS) device switch for 824 patients whose device was switched without an accompanying 
clinical visit or consultation
Type of ICS device switch No. (%) of patients
(n = 824)
Dry powder to metered-dose inhaler 437 (53)
Dry powder to dry powder inhaler (different brand) 106 (13)
Dry powder to breath-actuated inhaler 151 (18)
Breath-actuated to metered-dose inhaler 105 (13)
Breath-actuated to breath-actuated inhaler (different brand) 25 (3)
Table 3: Baseline and demographic characteristics of the two study cohorts: patients whose inhaled corticosteroid (ICS) device was 
switched (switched cohort) and the matched patients whose ICS device was not switched (control cohort)
Baseline Characteristic Switched Cohort
(n = 824)
Control Cohort
(n = 824)
p Value For Comparison
Sex* Female, n (%) 445 (54%) 445 (54%) N/A
Age* in yrs Median (IQR) 32 (15–50) 33 (14–51) 0.720**
Smoking status,* n (%) Non-smoker 399 (48%) 399 (48%) N/A
Smoker 240 (29%) 240 (29%)
Ex-smoker 54 (7%) 54 (7%)
Passive smoker 20 (2%) 20 (2%)
Data missing 111 (13%) 111 (13%)
Recorded rhinitis history,* n (%) 144 (17%) 144 (17%) N/A
Oral corticosteroid courses/yr,* n (%) 0 709 (86%) 709 (86%) N/A
1 76 (9%) 76 (9%)
2 20 (2%) 20 (2%)
3–8 19 (2%) 19 (2%)
Hospitalized for asthma,* n (%) 5 (0.6%) 5 (0.6%) N/A
Socioeconomic quintile, n (%) Lowest 309 (38%) 189 (23%) <0.001 §
2nd 49 (6%) 111 (13%)
3rd 297 (36%) 162 (20%)
4th 50 (6%) 167 (20%)
Highest 119 (14%) 192 (23%)
SABA daily dose, † median (IQR) 0.55 (0–1.64) 0.82 (0.27–1.64) <0.001**
Asthma consultations/yr Median (IQR) 0 (0–1) 1 (0–2)
Range 0–9 0–14
Asthma consultation rate, n (%) 0 524 (64%) 406 (49%) <0.001**
1 167 (20%) 212 (26%)
2 73 (9%) 103 (13%)
≥ 3 60 (7%) 103 (13%)
Recorded gastroesophageal disease, n (%) 45 (5%) 62 (8%) 0.089 §
Recorded cardiovascular disease, n (%) 33 (4%) 48 (6%) 0.087 §
Daily dose of ICS on index day, ‡ median (IQR) 400 μg (400–800) 400 μg (400–800) 0.137**
IQR = interquartile range; N/A = not applicable (because matching criterion); SABA = short-acting β-agonist
*Matching criterion (number of oral corticosteroid courses and hospitalizations for asthma were during the year before the index date).
†One dose of SABA was defined as salbutamol 200 μg or terbutaline 500 μg.
‡Dose equivalents for beclomethasone dipropionate, budesonide, fluticasone propionate, BDP in solution (QVAR®, Teva UK), and mometasone 
were in a ratio of 1:1:2:2:2, respectively.
§χ2 test, **Mann-WhitneyBMC Pulmonary Medicine 2009, 9:1 http://www.biomedcentral.com/1471-2466/9/1
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tation at baseline. Results were not substantially different
when the ICS dose was included in the analysis (OR, 1.89;
95% CI, 1.48 to 2.40; p < 0.001). Subsequent changes in
ICS device or dose during year 2 were recorded for 273
patients (33.1%) in the switched cohort and 183 patients
(22.2%) in the control cohort (p < 0.001).
During year 2, the daily use of short-acting β-agonist
increased in the switched cohort and decreased in the con-
Outcome of asthma treatment during study year 2 for patients whose inhaled corticosteroid device was switched without an  accompanying consultation (switched cohort) and matched controls: percentages of patients experiencing successful treat- ment, partially successful treatment, and unsuccessful treatment (see text for definitions) Figure 2
Outcome of asthma treatment during study year 2 for patients whose inhaled corticosteroid device was 
switched without an accompanying consultation (switched cohort) and matched controls: percentages of 
patients experiencing successful treatment, partially successful treatment, and unsuccessful treatment (see 
text for definitions).
Table 4: Impact of ICS inhaler device switch: the likelihood of asthma control among switched vs. control patients during the year 
after the switch
Unadjusted Analysis Logistic Regression Analysis*
OR (95% CI) p Value OR (95% CI) p Value
Successful treatment† 0.47 (0.37–0.58) <0.001 0.29 (0.19–0.44) <0.001
Unsuccessful treatment‡ 1.69 (1.39–2.01) <0.001 1.92 (1.47–2.56) <0.001
Subsequent change in ICS device 1.73 (1.39–2.16) <0.001 1.90 (1.50–2.42) <0.001
CI = confidence interval; ICS = inhaled corticosteroid; OR = odds ratio
*Adjusted for baseline confounding factors, including short-acting β-agonist use, asthma consultation rate, socioeconomic status, and prescribed ICS 
dose at the index date (time of ICS device switch).
†Successful treatment vs. partially successful/unsuccessful treatment.
‡Unsuccessful treatment vs. successful/partially successful treatment.BMC Pulmonary Medicine 2009, 9:1 http://www.biomedcentral.com/1471-2466/9/1
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trol cohort (Figure 3), and short-acting β-agonist use was
greater in the switched than in the control cohort (Table
5). The switched cohort used 0.38 extra doses/day of
short-acting β-agonist, compared with baseline use, than
the control cohort (95% CI, 0.22 to 0.53; p < 0.001).
Most patients did not require a course of oral corticoster-
oids during the outcome year, and there were no signifi-
cant differences between patient groups in the use of oral
corticosteroids during this time (Table 5) or in the change
in use from baseline. Similarly, there was no significant
difference in asthma consultation rate between patients in
switched and matched cohorts. Between year 1 and year 2,
consultation rates fell slightly by a mean of 0.09 (SD,
1.33) in the switched cohort and by 0.35 (SD, 1.59) in the
matched cohort. Thus, as compared with the baseline
period, the switched cohort had 0.26 more asthma con-
sultations in the outcome period than the matched cohort
(95% CI, 0.11 to 0.40; p < 0.001).
There were very few hospitalizations for asthma during
the study. Moreover, there was no significant difference
between cohorts in admissions for possible asthma (Table
5) or in the change from baseline to outcome periods in
admissions for possible asthma.
Mean (95% confidence interval) change in daily short-acting β-agonist (SABA) dose from the baseline year (year 1) to the out- come year (year 2) for patients with switched inhaled corticosteroid device and unswitched individually matched controls Figure 3
Mean (95% confidence interval) change in daily short-acting β-agonist (SABA) dose from the baseline year 
(year 1) to the outcome year (year 2) for patients with switched inhaled corticosteroid device and unswitched 
individually matched controls. One dose = salbutamol 200 μg or terbutaline 500 μg.BMC Pulmonary Medicine 2009, 9:1 http://www.biomedcentral.com/1471-2466/9/1
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Discussion
Switches in ICS device without clinical visit or consulta-
tion were associated with worsened asthma control in this
retrospective analysis of a large UK general practice data-
base. Patients whose ICS device was switched were signif-
icantly less likely to experience successful asthma
treatment and significantly more likely to experience
unsuccessful treatment than matched controls whose ICS
device had not been switched. When possible baseline
confounding factors were incorporated into the analysis,
there was an even stronger association of device switch
with lack of treatment success: patients with switched ICS
device had less than one third the chance of successful
treatment and were almost twice as likely to experience
unsuccessful treatment or another change in ICS device
compared with matched controls.
Use of short-acting β-agonist, a marker for asthma mor-
bidity [16], increased significantly in the year after switch-
ing among patients in the switched cohort relative to
controls. The number of hospitalizations for asthma and
the number of oral corticosteroid prescriptions were,
however, similar in the two cohorts during year 2.
We were able to identify over 100,000 individuals in the
database who had undergone a switch in ICS device, and
from these numbers were able to identify 55 practices
where five or more patients had been switched in a 3-
month period without a consultation, confirming our
clinical impression that switching of ICS devices without
a consultation is not an uncommon occurrence. While it
is possible that some consultations occurred but were not
recorded, given the multiple switching in these practices it
is unlikely that the cases of switch without consultation
are falsely identified. ICS device switching is typically
implemented as a cost-saving measure. Indeed, in this
study, the most common type of switch was from a dry
powder inhaler to a metered-dose inhaler, often the
cheapest inhaler device. Our study results would suggest,
however, that the potential for worsened asthma control,
and subsequent associated costs, may outweigh any
acquisition cost savings from the switch.
Worsening asthma control after ICS device switching
without a consultation could occur because of inadequate
dosing secondary to poor technique or because of reduced
patient adherence to therapy. Correct inhalation tech-
nique is necessary for attaining the full benefits of ICS.[9]
However, inhaler devices are difficult to use, especially the
metered-dose inhalers, which typically require the most
patient instruction on their use [17,18]. Moreover, patient
education and involvement in treatment decisions can
improve adherence to therapy [18-20]; thus, it is possible
that, without a clinical consultation, adherence was
reduced in the switched cohort and asthma control wors-
ened.
There are no other studies, to our knowledge, evaluating
the switching of inhaler devices without a consultation.
Surveys of the attitudes of health-care professionals and
patients about the interchangeability of dry powder inhal-
ers have consistently reported a generally negative attitude
about switching dry powder inhalers without input from
patient and physician [20-22].
This retrospective matched cohort study drew on data
from a large clinical database and as such is limited by the
completeness and accuracy of that database [23]. The
GPRD is a very large primary care database that is man-
aged with regular quality control and is considered to be
valid for respiratory epidemiological research [15,24]. In
theory, however, findings of statistical significance, but
not necessarily clinical significance, can emerge from the
evaluation of large data sets [23]. We limited our study
population to 824 patients who could be individually
matched to control patients using quite restrictive criteria.
The parameters that were different at baseline for the two
cohorts (short-acting β-agonist use, asthma consultations,
and socioeconomic status) were included as factors in the
regression model.
Table 5: Impact of ICS inhaler device switch: outcome measures for switched vs. control patients during the year after the switch
Outcome Measure Switched Cohort
(n = 824)
Control Cohort
(n = 824)
p Value For Comparison
Oral corticosteroid courses/yr, n (%) 0 698 (85%) 721 (88%) 0.197†
1 80 (10%) 65 (8%)
22 3  ( 3 % ) 1 2  ( 1 % )
3–11 23 (3%) 26 (3%)
Hospitalized for asthma, n (%) 3 (0.04%) 14 (1.70%) NS
SABA daily dose,* median (IQR) 0.82 (0.27–2.19) 0.55 (0–1.64) <0.001 §
Asthma consultation rate, n (%) 0 569 (69%) 514 (62%) 0.135†
1 155 (19%) 177 (21%)
≥ 2 100 (12%) 133 (16%)
ICS = inhaled corticosteroid; IQR = interquartile range; NS = not significant; SABA = short-acting β-agonist
*One dose of SABA was defined as salbutamol 200 μg or terbutaline 500 μg.
†χ2 test, §Mann-WhitneyBMC Pulmonary Medicine 2009, 9:1 http://www.biomedcentral.com/1471-2466/9/1
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We chose a composite measure of asthma control to assess
the impact of device switching because multiple outcome
measures are the best means of determining effectiveness
of asthma therapy [25]. The composite measures incorpo-
rated several measures of asthma morbidity, including
daily short-acting β-agonist dose, change in asthma con-
troller therapy, oral corticosteroid use, and hospitaliza-
tion for asthma. Inclusion of lung function tests would
have been impractical for this kind of study, as lung func-
tion tests are often not performed in primary care and are
limited in interpretation by ceiling effects. The inclusion
of OCS courses and hospitalizations means that a meas-
ure of severity was used to match patients, and surrogate
measures of severity were entered into the regression
model to reduce confounding.
There are a number of possible future studies given the
findings of this analysis. The impact of age (child com-
pared with adult) and long acting beta agonists are two
possible sub-group analyses. However, care would need to
be taken not to decrease the size of the cohort such that
the power of the study becomes too weak to make conclu-
sions from the findings.
Conclusion
In conclusion, switching of ICS inhaler devices without a
consultation is most commonly used for substitution of a
cheaper metered-dose inhaler in place of a dry powder
inhaler. Switching ICS inhaler devices without a consulta-
tion was associated with worsened asthma control. There-
fore, the possible costs of adverse effects on asthma
control should be weighed against savings in acquisition
costs before instituting mass switching of ICS inhaler
devices. Switching ICS inhaler devices without a face-to-
face evaluation and consultation is inadvisable.
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